Lennox-Gastaut Syndrome: Current Strategies
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
1 ILAE Classification & Definition of Epilepsy Syndromes in the Neonate
ILAE Classification & Definition of Epilepsy Syndromes in the Neonate and Infant: Position Statement by the ILAE Task Force on Nosology and Definitions Authors: Sameer M Zuberi1, Elaine Wirrell2, Elissa Yozawitz3, Jo M Wilmshurst4, Nicola Specchio5, Kate Riney6, Ronit Pressler7, Stephane Auvin8, Pauline Samia9, Edouard Hirsch10, O Carter Snead11, Samuel Wiebe12, J Helen Cross13, Paolo Tinuper14,15, Ingrid E Scheffer16, Rima Nabbout17 1. Paediatric Neurosciences Research Group, Royal Hospital for Children & Institute of Health & Wellbeing, University of Glasgow, Member of European Reference Network EpiCARE, Glasgow, UK. 2. Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester MN, USA. 3. Isabelle Rapin Division of Child Neurology of the Saul R Korey Department of Neurology, Montefiore Medical Center, Bronx, NY USA. 4. Department of Paediatric Neurology, Red Cross War Memorial Children’s Hospital, Neuroscience Institute, University of Cape Town, South Africa. 5. Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesu’ Children’s Hospital, IRCCS, Member of European Reference Network EpiCARE, Rome, Italy 6. Neurosciences Unit, Queensland Children's Hospital, South Brisbane, Queensland, Australia. Faculty of Medicine, University of Queensland, Queensland, Australia. 7. Clinical Neuroscience, UCL- Great Ormond Street Institute of Child Health, London, UK. Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children NHS Foundation Trust, Member of European Reference Network EpiCARE London, UK 8. Université de Paris, AP-HP, Hôpital Robert-Debré, INSERM NeuroDiderot, DMU Innov-RDB, Neurologie Pédiatrique, Member of European Reference Network EpiCARE, Paris, France. 9. Department of Paediatrics and Child Health, Aga Khan University, East Africa. 1 10. Neurology Epilepsy Unit “Francis Rohmer”, INSERM 1258, FMTS, Strasbourg University, France. -
Research Quarterly
Research Quarterly A dream you dream alone is only a dream. A dream you dream together is reality. – Yoko Ono In this issue of the Quarterly, we highlight some of the partnerships our research team has developed to make a bigger impact for people with epilepsy. Our research covers the entire spectrum of discovery – from idea to market. We cannot do it alone. On page 2, we provide updates on the Rare Epilepsy Network (REN), a coalition of nearly 30 different organizations working together to facilitate research that improves the outcomes of those living with rare epilepsies. On page 3, clinicians from Thomas Jefferson University Hospital in Philadelphia, PA reflect on how the Epilepsy Foundation’s support early on in their career encouraged them to pursue research within the field. Supporting the development of early career investigators is done in proud partnership with the American Epilepsy Society (AES). This collaborative effort ensures that we can pool our resources, reduce administrative cost and maximize impact. Supporting our professional workforce is one of the ways in which we can ensure that the best and the brightest are tackling the challenges that our community face. We could not do this without our partners at AES. On page 5, we provide staff reports on the conferences attended this past quarter from the Nonprofits Forum at the National Institutes of Health, to meeting new companies at Bio Conference, to facilitating discussions on how medical devices can impact SUDEP and epilepsy care with the Food and Drug Administration. We are creating a research environment in which partnerships spur innovation and exciting discoveries to end epilepsy. -
The Art of Epilepsy Management
FOCAL EPILEPSY AND SEIZURE SEMIOLOGY Piradee Suwanpakdee, MD. Division of Neurology Department of Pediatrics Phramongkutklao Hospital OUTLINE • Focal onset seizure classification • The definition of semiology • How can we get the elements of semiology? Focal seizures • Originate within networks limited to one hemisphere • May be discretely localized or more widely distributed.… www.ilae.org What is the seizure semiology? • Seizure semiology is an expression of activation and disinhibition of cerebral areas • It thus provides some information what cerebral areas are “involved” during a seizure Symptomatogenic areas Left hemisphere lateral aspect Mesial aspect Symptomatogenic areas Left Insula How can we get the elements of seizure semiology? • The information on semiology comes from patient’s and witness’ history • Video EEG provides objective data on seizure semiology • Seizure classification aims to intellectually organise and summarise information about seizure semiology Notes • Atonic seizures and epileptic spasms would not have level of awareness specified • Pedalling grouped in hyperkinetic rather than automatisms (arbitrary) • Cognitive seizures • impaired language • other cognitive domains • positive features eg déjà vu, hallucinations, perceptual distortions • Emotional seizures: anxiety, fear, joy, etc Focal onset aware seizure • This term replaces simple partial seizure • A seizure that starts in one area of the brain and the person remains alert and able to interact is called a focal onset aware seizure. • These seizures are brief, lasting seconds to less than 2 minutes. Focal clonic seizure • Indicate involvement of contralateral primary motor cortex • Reliability is good Epilepsia partialis continua focal motor status involving a small portion of the sensorimotor cortex Focal Onset Impaired Awareness Seizures • A seizure that starts in one area of the brain and the person is not aware of their surroundings • Focal impaired awareness seizures typically last 1 to 2 minutes. -
Dravet Syndrome
NAVIGATING LIFE WITH DRAVET SYNDROME Information and support for parents and caregivers NAVIGATING LIFE WITH DRAVET SYNDROME Information and support for parents and caregivers Contributors: Dr. Martina E. Bebin Dr. Robert Flamini Dr. Kelly Knupp Dr. Linda Laux Dr. Scott Perry Dr. Joseph Sullivan Dr. James Wheless Dr. Elaine Wirrell Dravet Syndrome Foundation Executive Team 3 TABLE OF CONTENTS INTRODUCTION 6 Caring for people with Dravet syndrome 24 QUESTIONS 8 14. What should I do when my child 24 has a seizure? Overview of Dravet syndrome 8 15. What are trigger factors for seizures? 25 1. What is Dravet syndrome? 8 16. What daily life difficulties might my 26 2. What is the cause of Dravet syndrome? 10 child face? 3. How is Dravet syndrome diagnosed? 10 Family life 27 4. Is Dravet syndrome inherited? Are my 11 17. How will our family’s daily life change? 27 other children at risk? 18. How do I explain Dravet syndrome 28 5. What type of doctors and specialists 13 to my other children? might my child need to see regularly? 19. How do I explain Dravet syndrome 29 6. Can childhood vaccines cause Dravet 14 to my family and friends? syndrome? Should I vaccinate my child? Dravet syndrome in childhood 31 Seizures and treatments 15 20. What is the course of Dravet syndrome 31 7. What types of seizures are usually 15 in childhood? seen in Dravet syndrome? 21. Can my child attend school? 33 8. What is SUDEP? 16 Dravet syndrome in puberty and adulthood 35 9. Besides seizures, what are the other 18 medical issues related to Dravet syndrome? 22. -
Clinicians Using the Classification Will Identify a Seizure As Focal Or Generalized Onset If There Is About an 80% Confidence Level About the Type of Onset
GENERALIZED ONSET SEIZURES Generalized onset seizures are not characterized by level of awareness, because awareness is almost always impaired. Generalized tonic-clonic: Immediate loss of Generalized epileptic spasms: Brief seizures with awareness, with stiffening of all limbs (tonic phase), flexion at the trunk and flexion or extension of the followed by sustained rhythmic jerking of limbs and limbs. Video-EEG recording may be required to face (clonic phase). Duration is typically 1 to 3 minutes. determine focal versus generalized onset. The seizure may produce a cry at the start, falling, tongue biting, and incontinence. Generalized typical absence: Sudden onset when activity stops with a brief pause and staring, Generalized clonic: Rhythmical sustained jerking of sometimes with eye fluttering and head nodding or limbs and/or head with no tonic stiffening phase. other automatic behaviors. If it lasts for more than These seizures most often occur in young children. several seconds, awareness and memory are impaired. Recovery is immediate. The EEG during these seizures Generalized tonic: Stiffening of all limbs, without always shows generalized spike-waves. clonic jerking. Generalized atypical absence: Like typical absence Generalized myoclonic: Irregular, unsustained jerking seizures, but may have slower onset and recovery and of limbs, face, eyes, or eyelids. The jerking of more pronounced changes in tone. Atypical absence generalized myoclonus may not always be left-right seizures can be difficult to distinguish from focal synchronous, but it occurs on both sides. impaired awareness seizures, but absence seizures usually recover more quickly and the EEG patterns are Generalized myoclonic-tonic-clonic: This seizure is like different. -
Dravet Syndrome—The Polish Family's Perspective Study
Journal of Clinical Medicine Article Dravet Syndrome—The Polish Family’s Perspective Study Justyna Paprocka 1,*, Anita Lewandowska 2, Piotr Zieli ´nski 2 , Bartłomiej Kurczab 2, Ewa Emich-Widera 1 and Tomasz Mazurczak 3 1 Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; [email protected] 2 Students’ Scientific Society, Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; [email protected] (A.L.); [email protected] (P.Z.); [email protected] (B.K.) 3 Clinic of Paediatric Neurology, National Research Institute of Mother and Child, 01-211 Warsaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Aim: The aim of the paper is to study the prevalence of Dravet Syndrome (DS) in the Polish population and indicate different factors other than seizures reducing the quality of life in such patients. Method: A survey was conducted among caregivers of patients with DS by the members of the Polish support group of the Association for People with Severe Refractory Epilepsy DRAVET.PL. It included their experience of the diagnosis, seizures, and treatment-related adverse effects. The caregivers also completed the PedsQL survey, which showed the most important problems. The survey received 55 responses from caregivers of patients with DS (aged 2–25 years). Results: Prior to the diagnosis of DS, 85% of patients presented with status epilepticus lasting more than 30 min, and the frequency of seizures (mostly tonic-clonic or hemiconvulsions) ranged from 2 per week to hundreds per day. -
Seizure Disorders
Seizure Disorders Author Anthony Murro, M.D. Medical College of Georgia Epilepsy Program Department of Neurology Medical College of Georgia Augusta, GA 30912 Contents · Seizure Definitions · Types of Seizures · Partial Seizures · Generalized Seizures · Automatisms · Post-ictal state · Evolution of seizure type · Provoked Seizures · Causes of provoked seizures · Causes of unprovoked seizures · Electroencephalogram · Neuroimaging · Epilepsy syndromes o Temporal lobe epilepsy: o Frontal lobe epilepsy: o Occipital lobe epilepsy: o West Syndrome o Lennox Gastaut Syndrome o Benign partial epilepsy syndromes o Childhood absence epilepsy o Juvenile myoclonic epilepsy (JME) o Simple Febrile Seizure o Complex Febrile Seizure o Neonatal seizures · Anticonvulsant therapy o When to start and stop anticonvulsant therapy o Principles of anticonvulsant therapy o Anticonvulsant side effects o Phenytoin o Carbamazepine o Phenobarbital o Valproate o Lamotrigine o ACTH/Corticosteroid o Oxcarbazepine o Zonisamide · Status Epilepticus · Drug Therapy for status epilepticus · Epilepsy Surgery · Counseling and patient education · Self assessment examination · Examination answers · References · Disclaimer · Permitted Use Statement Seizure Definitions · An epileptic seizure is a disorder of abnormal synchronous electrical brain activity. · A clinical seizure is a epileptic seizure with symptoms. · A subclinical seizure is a epileptic seizure without symptoms. · A non-epileptic seizure (pseudoseizure) is a disorder with symptoms similar to a epileptic seizure. However, a non-epileptic seizure is not caused by abnormal synchronous electrical brain activity. · A cryptogenic seizure is a seizure that occurs from an unknown cause. Older publications use idiopathic to describe a seizure of unknown etiology but the current ILAE guidelines discourage the use of idiopathic for describing a seizure of unknown etiology. · A symptomatic seizure is a seizure that occurs from a known or suspected brain insult known to increase the risk of developing epilepsy. -
10|18 Stiripentol Use in Children with Refractory Seizures
PEDIATRIC PHARMACOTHERAPY Volume 24 Number 10 October 2018 Stiripentol Use in Children with Refractory Seizures Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS tiripentol was approved by the Food and concentrations of 2, 6.5, and 14.1 mg/L between S Drug Administration (FDA) on August 20, 2 and 4 hours post-dose.6 The drug is highly 2018 as adjunctive therapy with clobazam for the protein bound (99%), with an estimated treatment of seizures associated with Dravet elimination half-life of 5 to 13 hours. Although syndrome in patients 2 years of age and older.1,2 It the metabolism of stiripentol has not been fully is not currently approved as monotherapy. Dravet delineated, it is known to be a substrate for syndrome, also referred to as severe myoclonic CYP1A2, CYP2C19, and CYP3A4. As a result of epilepsy of infancy, is a rare disorder its reliance on both hepatic and renal clearance, characterized by seizures unresponsive to most use of stiripentol in patients with moderate to antiepileptics, motor impairment, and severe hepatic or renal impairment is not developmental disabilities. Nearly a quarter of recommended.2 patients die during childhood. Approximately 70% of patients have a mutation in the sodium The first published study to evaluate stiripentol channel alpha-1 subunit gene (SCN1A) leading to plasma concentrations enrolled 10 children and malfunction or loss of function in GABAergic adolescents from 6 to 16 years of age with neurons.3 As a treatment for a rare disorder, refractory atypical absence seizures.7 The patients stiripentol has been designated as an orphan drug received a mean maintenance dose of 57 by both the European Medicines Agency and the mg/kg/day (range 34-78 mg/kg/day) during the 4- FDA. -
Report of the ILAE Classification Core Group
Epilepsia, 47(9):1558–1568, 2006 Blackwell Publishing, Inc. C 2006 International League Against Epilepsy Special Article Report of the ILAE Classification Core Group Jerome Engel, Jr., Chair Reed Neurological Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A. Summary: A Core Group of the Task Force on Classification is to present a list of seizure types and syndromes to the ILAE and Terminology has evaluated the lists of epileptic seizure types Executive Committee for approval as testable working hypothe- and epilepsy syndromes approved by the General Assembly in ses, subject to verification, falsification, and revision. This re- Buenos Aires in 2001, and considered possible alternative sys- port represents completion of this work. If sufficient evidence tems of classification. No new classification has as yet been subsequently becomes available to disprove any hypothesis, the proposed. Because the 1981 classification of epileptic seizure seizure type or syndrome will be reevaluated and revised or dis- types, and the 1989 classification of epilepsy syndromes and carded, with Executive Committee approval. The recognition of epilepsies are generally accepted and workable, they will not specific seizure types and syndromes, as well as any change be discarded unless, and until, clearly better classifications have in classification of seizure types and syndromes, therefore, will been devised, although periodic modifications to the current clas- continue to be an ongoing dynamic process. A major purpose of sifications may be suggested. At this time, however, the Core this approach is to identify research necessary to clarify remain- Group has focused on establishing scientifically rigorous cri- ing issues of uncertainty, and to pave the way for new classifica- teria for identification of specific epileptic seizure types and tions. -
Epilepsy & My Child Toolkit
Epilepsy & My Child Toolkit A Resource for Parents with a Newly Diagnosed Child 136EMC Epilepsy & My Child Toolkit A Resource for Parents with a Newly Diagnosed Child “Obstacles are the things we see when we take our eyes off our goals.” -Zig Ziglar EPILEPSY & MY CHILD TOOLKIT • TABLE OF CONTENTS Introduction Purpose .............................................................................................................................................5 How to Use This Toolkit ....................................................................................................................5 About Epilepsy What is Epilepsy? ..............................................................................................................................7 What is a Seizure? .............................................................................................................................8 Myths & Facts ...................................................................................................................................8 How is Epilepsy Diagnosed? ............................................................................................................9 How is Epilepsy Treated? ..................................................................................................................10 Managing Epilepsy How Can You Help Manage Your Child’s Care? ...............................................................................13 What Should You Do if Your Child has a Seizure? ............................................................................14 -
Stoke Therapeutics Presents Preclinical Data from Studies Of
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome December 7, 2019 New data from electroencephalography (EEG) recordings showed 76% of Dravet syndrome (DS) mice treated with STK-001 were seizure free compared to 48% of placebo-treated mice An 80% reduction in the average number of spontaneous seizures was also observed among treated DS mice Data support the clinical development of STK-001 as a potential new medicine for Dravet syndrome, a severe and progressive genetic epilepsy BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 7, 2019-- Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced preclinical data from studies of STK-001 that showed significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome (DS). New data from electroencephalography (EEG) recordings showed 76% (16/21) of DS mice treated with STK-001 were seizure free compared to 48% (10/21) that were treated with a placebo. An 80% reduction in the average number of spontaneous seizures (3 seizures vs 16 seizures) was also observed among treated DS mice compared to placebo. EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible. These data were presented in a poster session at the American Epilepsy Society (AES) Annual Meeting in Baltimore. “The data on STK-001 from this mouse model give us confidence in our approach to treating the underlying cause of Dravet syndrome by restoring Nav1.1 protein expression to near normal levels,” said Edward M. -
Genetic Epilepsy with Febrile Seizures Plus
Genetic epilepsy with febrile seizures plus Description Genetic epilepsy with febrile seizures plus (GEFS+) is a spectrum of seizure disorders of varying severity. GEFS+ is usually diagnosed in families whose members have a combination of febrile seizures, which are triggered by a high fever, and recurrent seizures (epilepsy) of other types, including seizures that are not related to fevers ( afebrile seizures). The additional seizure types usually involve both sides of the brain ( generalized seizures); however, seizures that involve only one side of the brain (partial seizures) occur in some affected individuals. The most common types of seizure in people with GEFS+ include myoclonic seizures, which cause involuntary muscle twitches; atonic seizures, which involve sudden episodes of weak muscle tone; and absence seizures, which cause loss of consciousness for short periods that appear as staring spells. The most common and mildest feature of the GEFS+ spectrum is simple febrile seizures, which begin in infancy and usually stop by age 5. When the febrile seizures continue after age 5 or other types of seizure develop, the condition is called febrile seizures plus (FS+). Seizures in FS+ usually end in early adolescence. A condition called Dravet syndrome (also known as severe myoclonic epilepsy of infancy or SMEI) is often considered part of the GEFS+ spectrum and is the most severe disorder in this group. Affected infants typically have prolonged seizures lasting several minutes (status epilepticus), which are triggered by fever. Other seizure types, including afebrile seizures, begin in early childhood. These types can include myoclonic or absence seizures. In Dravet syndrome, these seizures are difficult to control with medication, and they can worsen over time.